Parse Biosciences today announced their commitment to support researchers from the Icahn School of Medicine at Mount Sinai in generating one of the largest single cell datasets focused on ...

A fearless Antigone, refusing to allow the dishonored body of her murdered brother Polynices to be devoured by vultures | dG1fUFpGbzh6SWcxUWM ...

Fusion genes, arising from abnormal chromosomal rearrangements, are gaining recognition as pivotal players in cancer ...

Fusion genes, arising from abnormal chromosomal rearrangements, are gaining recognition as pivotal players in cancer ...

DelveInsight’s, “Chronic Lymphocytic Leukemia Pipeline Insight 2025” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Chronic Lymphocytic Leukemia (CLL) pipeline ...

Revolutionary advancements in blood cancer treatment, from targeted therapy to gene editing, promise more effective and ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers ...

This single-arm, multicenter Phase II study assessed the efficacy and safety of olverembatinib in combination with the VP (vindesine+prednisone) regimen (OVP) in the first-line treatment of adult ...

SAR-Bombesin targets the gastrin-releasing peptide receptor (GRPR), a promising pan-cancer target expressed in a number of ...

Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in peripheral T-cell lymphoma (PTCL ...

The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on ...